What is BioIntelliSense?
BioIntelliSense offers advanced health monitoring and clinical intelligence solutions, leveraging a medical-grade Data-as-a-Service (DaaS) platform. This innovative system captures vital signs, physiological biometrics, and symptomatic events through a wearable body sensor. Based in Redwood City, CA, BioIntelliSense is at the forefront of transforming healthcare delivery by providing actionable insights derived from continuous patient data, enabling proactive and personalized care.
How much funding has BioIntelliSense raised?
BioIntelliSense has raised a total of $70M across 2 funding rounds:
Series A
$25M
Series B
$45M
Series A (2019): $25M with participation from Jonathan Weiner and Fresenius Medical Care North America
Series B (2021): $45M led by 7wireVentures and Pendrell
Key Investors in BioIntelliSense
Fresenius Medical Care North America
Fresenius Medical Care North America is a prominent entity in the healthcare sector, likely focusing on dialysis and related medical services. Their participation suggests a strategic interest in technologies that enhance patient monitoring and clinical intelligence, potentially integrating BioIntelliSense's solutions into their existing care networks.
7wireVentures
7wire Ventures is a venture capital firm specializing in early-stage digital health companies. Their investment in BioIntelliSense aligns with their mission to revolutionize healthcare through innovative solutions that empower informed and connected health consumers, likely focusing on the DaaS platform's potential for improving health outcomes.
Pendrell
Pendrell Corporation is known for investing in and developing businesses with unique, IP-protected technologies. Their involvement with BioIntelliSense suggests an appreciation for the company's proprietary wearable sensor technology and DaaS platform, potentially seeing value in its intellectual property and market disruption potential.
What's next for BioIntelliSense?
The recent major strategic investment signals BioIntelliSense's transition into a scaling phase, likely focusing on expanding its market reach and further developing its technological capabilities. This capital infusion is expected to accelerate the adoption of its DaaS platform across healthcare providers and potentially new markets. Strategic partnerships and further product innovation will be key as BioIntelliSense aims to solidify its position as a leader in remote patient monitoring and clinical intelligence.
See full BioIntelliSense company page
